Running discussion on SP, page-11038

need to disagree with the timing comment.
if the initial study was just delayed because of a deadline miss, it'd be an unnecessary concern. and yes i acknowledge for those who were hoping to trade the news yeah sure sucks for them as theyre now in the dark on timing.

Given management highlighted that they had infact increased the scope of the study and this was the reason for the extension of the release to market it's actually extremely positive.

in my experience you don't extend the scope of studies unless the initial studies were proving to be quite favourable.

all in all it fastracks the process. one study, one announcement. the extension was just a green light for me that whatever theyd worked out in the last couple months had warranted investigating the next step.

in unrelated matters, i havent seen an updated forward evaluation of avz's MC with some projected costs and sales figures to work out the hypothetical net value. reason being theres one knocked up for gxy (not a holder) or maybe in was billyen over at agy (not a holder)

Would love for one of the stalwarts of avz to utilise the same assumptions (where applicable) to see how avz stacks up in terms of comparible calculated upside.

SF2TH